Form 4: Provectus Biopharmaceuticals CEO Edward Pershing Reports Conversion of Convertible Note into Preferred Stock

CEO Edward Pershing reports the conversion of a convertible note into Series D-1 Preferred Stock of Provectus Biopharmaceuticals.

Summary

• On April 11, 2025, Edward Pershing, CEO of Provectus Biopharmaceuticals, reported the conversion of an 8% unsecured convertible promissory note into 7,551 shares of Series D-1 Convertible Preferred Stock.
• The conversion occurred at a price of $2.862 per share.
• Each share of Series D-1 Preferred Stock is convertible into 10 shares of common stock.
• The Series D-1 Convertible Preferred Stock will automatically convert into common stock on June 20, 2026, unless earlier converted.
• Following the reported transaction, Pershing beneficially owns 2,063,538 shares of common stock and 1,735,000 shares of Series D-1 Convertible Preferred Stock.

Sentiment

Score: 5

Explanation: This is a routine filing related to a pre-existing agreement, so it's neutral in sentiment.

Future Outlook

The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Key Dates

Keywords

Form 4, beneficial ownership, Series D-1 Convertible Preferred Stock, convertible note, Edward Pershing, Provectus Biopharmaceuticals, PVCT, conversion